#Neuroscience
14 articles tagged with “Neuroscience”
Issue #39 — The Insight Advantage: Why ADHD Founders Solve Creative Problems Better
New Drexel research shows strong ADHD symptoms predict superior creative problem-solving via sudden insight. Here's how to redesign your decision process around incubation instead of forcing analytical frameworks that fight your neurology.
Issue #38 — The Demanding Life Paradox: Why Your Startup Is Your Best ADHD Treatment
The longest-running ADHD study on Earth shows remission tracks environmental demand, not rest. For founders, your startup may be the most effective ADHD intervention you've ever accidentally implemented.
Issue #35 — What ADHD Medication Actually Does (It's Not What You Were Told)
The largest brain-imaging study of ADHD meds found stimulants don't sharpen attention — they pre-reward the brain. Here's how that changes when and how founders should use medication strategically.
Issue #34 — Your Brain Goes to Sleep While You Work — Here's the Neuroscience
New Monash University research shows ADHD brains slip into brief slow-wave sleep states while working. Zoning out isn't laziness — it's neurology. Here's how to build your day around it.
Issue #31 — The Evidence-Based ADHD Founder: What 200 Studies Actually Say Works
A February 2026 review synthesized 200+ ADHD meta-analyses. Three interventions actually work; everything else is noise. Here's the evidence hierarchy and how to build your protocol around it.
Issue #28 — The Urgency Engine: Why ADHD Founders Build on Adrenaline (And Why It Always Burns Out)
ADHD founders unconsciously design businesses around constant urgency because their brains need the adrenaline to function. Here's the neuroscience of why that engine burns out, and how to manufacture controlled urgency instead of waiting for real crises.
Issue #24 — Your Brain's True Procrastination Calculus: The Energy Budget Model
Your ADHD brain isn't lazy — it's running a metabolic ROI calculation and vetoing tasks that look like bad energy investments. New neuroscience reveals how to stop fighting the budget committee and start submitting better proposals.
Issue #23 — The Non-Stimulant Revolution Is 40 Days Away: What Centanafadine Means for ADHD Founders
The FDA decides on centanafadine — the first triple-reuptake inhibitor for ADHD — on July 24. Here's what the mechanism actually does, which founder profiles it helps, and why the stimulant-or-suffer binary is about to die.
Issue #21 — The Mirage That Built Your ADHD Identity
The 2007 study that told a generation of ADHD adults their brains just mature late was a statistical mirage. New PNAS research resets the science — and your operating model.
Issue #20 — The Dose Nobody Told You About: What the Lancet's ADHD Sweet Spot Study Means for Founders
A new Lancet Psychiatry meta-analysis mapped the exact dose where every major ADHD drug stops working better and starts costing you more. Here's the prescriber conversation to have this week.
Issue #19 — Your ADHD Isn't One Condition — Brain Scans Just Revealed Three
A new JAMA Psychiatry study used 1,154 MRI scans to prove ADHD is three biologically distinct conditions. Here's how to know which biotype is running your company — and how to build decision-making buffers around it.
Issue #18 — The Third Brain: What the JAMA Biotype Study Means for the ADHD Founder Who's Never Fit
A new JAMA Psychiatry study of 1,154 brain scans found ADHD is at least three neurobiologically distinct conditions — and the extreme third biotype is the one founders crash hardest on.
Issue #12 — ADHD Is Three Brains, Not One — And That Changes Everything
A landmark JAMA Psychiatry study identified three neurobiologically distinct types of ADHD. If ADHD advice has never quite fit you, this is why — and what to do about it.
Issue #10 — The Brain Is The Next Platform (But Are ND Founders Ready?)
🎯 TL;DR Forbes Business Council just declared "The Brain Is The Next Platform" — mining companies are evaluating EEG headsets to measure cognitive load in real-time. This week: What br...